# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Gregory Renza maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Outperform and lowers the price tar...
Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and lowers the price target from $...
Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell ...
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate ...